A. FURTHER INFORMATION ABOUT OUR GROUP

1. Incorporation

Our Company was established as a limited liability company in the PRC on May 9, 2004, and further converted into a joint stock company with limited liability on August 30, 2022.

As of the date of this Document, our registered office and head office are located at 1101–1108, 11/F, No. 11, Xiancun Road, Tianhe District, Guangzhou, Guangdong. Accordingly, our Company's corporate structure and Articles of Association are subject to the relevant laws and regulations of the PRC. A summary of the relevant provisions of our Articles of Association is set out in "Summary of Articles of Association" in Appendix III to this Document.

Our Company has established a principal place of business in Hong Kong SAR at 31/F, Tower Two, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong. We have been registered with the Registrar of Companies in Hong Kong SAR as a non-Hong Kong company under Part 16 of the Companies Ordinance on September 25, 2025. Mr. Wong Chun Wing Samuel (黃俊穎), one of our joint company secretaries, has been appointed as the authorized representative of our Company for the acceptance of the service of process on behalf of our Company in Hong Kong SAR. The address for the service of process is the same as our principal place of business in Hong Kong SAR.

2. Changes in Share Capital of Our Company

As of the date of our establishment, our registered capital was RMB5,000,000.

Save as disclosed in the section headed "History, Development and Corporate Structure" in this Document, there were no change in the shares or registered capital of our Company within the two years immediately preceding the date of this Document.

For more details, see "History, Development and Corporate Structure". Save as aforesaid, as of the Latest Practicable Date, there had been no alterations of our share capital within the two years preceding the date of publication of this Document.

3. Changes in the Share Capital of Our Subsidiaries

A summary of the corporate information and the particulars of our subsidiaries are set out in Note 1 to the Accountant's Report as set out in Appendix I to this Document.

The following sets out the changes in share capital of our major operating subsidiaries that made a material contribution to our results of operations during the two years immediately preceding the date of this Document:

On May 29, 2025, the registered share capital of Rong Tai Pharmaceutical (Hubei) Co. Ltd. (融泰醫藥(湖北)有限公司) was increased from RMB4,600,000 to RMB20,000,000. On June 9, 2025, it was further increased from RMB20,000,000 to RMB25,000,000.

For details of our principal operating subsidiaries, please see the section headed "History, Development and Corporate Structure—Our Major Subsidiaries".

Save as disclosed above, there has been no alteration in the share capital of any of the principal operating entities of the Company within the two years immediately preceding the date of this Document.

4. Resolutions of Our Shareholders in Relation to the [REDACTED]

At the general meeting of our Company held on September 10, 2025, among other things, the following resolutions were passed by the Shareholders:

(i) the sub-division of the Shares with nominal value of RMB1.0 each on the basis of 1:10, effective immediately prior to the **[REDACTED]**, and taking into account the Share Subdivision, the issue of H Shares of nominal value of RMB0.1 each and such H Shares be **[REDACTED]** on the Stock Exchange;

(ii) the number of H Shares to be issued before the exercise of the **[REDACTED]** shall not be more than 25% of the total issued share capital of our Company, and granting the **[REDACTED]** the **[REDACTED]** of no more than 15% of the number of H Shares issued pursuant to the **[REDACTED]**;

(iii) upon completion of the **[REDACTED]** and taking into account the Share Subdivision, the **[REDACTED]** Unlisted Shares in aggregate will be converted into H Shares on a one-for-one basis;

(iv) subject to the completion of the **[REDACTED]**, the granting of a general mandate to the Board to allot and issue H Shares (including any sale of treasury Shares) at any time within a period up to the date of the conclusion of the next annual general meeting of the Shareholders or the date on which the Shareholders pass resolution to revoke or change such mandate, whichever is earlier, and to handle the approval or filing of the CSRC, the Stock Exchange and/or other relevant regulatory authorities with respect to in the aforementioned general mandate in accordance with the relevant laws and regulations, provided that, the number of H Shares to be allotted or issued shall not exceed 20% of the number of H Shares in issue as of the **[REDACTED]**;

(v) subject to the completion of the **[REDACTED]**, the conditional adoption of the Articles of Association, which shall become effective on the **[REDACTED]** and the authorization of the Board to amend the Articles of Association in accordance with relevant laws and regulations and upon the request from the Stock Exchange and relevant PRC regulatory authorities; and

(vi) authorization of the Board and its authorized persons to handle all matters relating to, among other things, the **[REDACTED]**, the issue and **[REDACTED]** of the H Shares.

5. Restriction on Share Repurchases

For details of the restrictions on the share repurchase by our Company, please refer to "Summary of the Articles of Association" in Appendix III to this Document.

6. Corporate Reorganization

We have not gone through any corporate reorganization for the purpose of the **[REDACTED]**. For details of the history and development of our Company, see "History, Development and Corporate Structure."

7. Summary of Material Contracts

The following contracts (not being contracts entered into in the ordinary course of business) have been entered into by us within the two years preceding the date of this Document and are or may be material:

(a) the **[REDACTED]**.

8. Intellectual Property Rights of Our Group

(a) Trademarks

(i) Registered Trademarks

As of the Latest Practicable Date, we had registered the following trademarks which we consider to be or may be material to our business:

No.	Trademark	Place of Registration	Registration No.	Registered Owner	Class	Registration Date	Expiry Date
1.	融泰药业	PRC	51046932	Company	35	May 28, 2022	May 27, 2032
2.		PRC	59133045	Company	35	May 21, 2022	May 20, 2032
3.	宜康思	PRC	50685794	Company	35	June 28, 2021	June 27, 2031
4.	宜康思	PRC	59892730	Guangzhou Yikangsi	35	June 28, 2022	June 27, 2032
5.		PRC	59299992	Guangzhou Yikangsi	35	March 14, 2022	March 13, 2032
6.		PRC	59295820	Guangzhou Yikangsi	35	March 14, 2022	March 13, 2032
7.	瑞优云	PRC	68666218	Wuhan Yikangsi	35	June 14, 2023	June 13, 2033

(b) Domain Names

As of the Latest Practicable Date, we had registered and maintained ownership to the following domain name in China which we consider to be or may be material to our business:

No.	Domain	Registrant	Expiry Date
1.	rongtaipharm.com	Company	May 8, 2027

Save as disclosed above, as of the Latest Practicable Date, there were no other patents, trade or service marks, intellectual or industrial property rights which are or may be material in relation to our business.

B. FURTHER INFORMATION ABOUT OUR DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

1. Directors

(i) Disclosure of Interests

Saved as disclosed below, immediately following completion of the **[REDACTED]** and the Conversion of Unlisted Shares into H Shares (assuming that the **[REDACTED]** is not exercised), so far as our Directors are aware, none of our Directors or chief executive has any interests or short positions in our Shares, underlying shares and debentures of our Company or any associated corporations (within the meaning of Part XV of the SFO) which will have to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to Section 352 of the SFO, to be recorded in the register referred to therein or which will be required to be notified to our Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Companies contained in the Listing Rules.

			Shares held as at the Latest Practicable Date		Shares held immediately following the Share Subdivision, the completion of the [REDACTED] and the Conversion of Unlisted Shares into H Shares			
Name	Positions	Nature of Interest(1)	Class of Shares	Number	Class of Shares	Number	% of shareholding in the H Shares (as appropriate)(2)	% of shareholding in the total issued share capital of our Company(2)
Mr. Chen(3)	Executive Director	Beneficial owner	Unlisted Shares	2,299,218	H Shares	[REDACTED]	[REDACTED]	[REDACTED]
		Interest in controlled corporation	Unlisted Shares	2,578,125	H Shares	[REDACTED]	[REDACTED]	[REDACTED]

Notes:

(1) All interests stated are long positions.

(2) The calculation is based on the total number of **[REDACTED]** H Shares in issue immediately upon completion of the **[REDACTED]** and the Conversion of Unlisted Shares into H Shares (assuming the **[REDACTED]** is not exercised).

(3) Mr. Chen is the sole general partner of Guangzhou Changfeng. As such, under the SFO, Mr. Chen is deemed to be interested in the Shares held by Guangzhou Changfeng.

(ii) Particulars of Service Contracts

Each of our Directors has entered into a service contract with our Company. The principal particulars of these service agreements are: (a) each of the agreements is for a term of three years following their respective appointment date; and (b) each of the agreements is subject to termination in accordance with their respective terms. The service agreements may be renewed in accordance with our Articles of Association and the applicable rules.

Save as disclosed above, our Company has not entered, and does not propose to enter, into any service contracts with any of the Directors in their respective capacities as Directors (other than contracts expiring or determinable by the employer within one year without the payment of compensation (other than statutory compensation)).

(iii) Directors' Remuneration

For details of the Directors' remuneration, see "Directors and Senior Management—Remuneration of Directors" and Note 10 to the Accountants' Report as set out in Appendix I to this Document.

2. Substantial Shareholders

(i) Interest in the Shares of Our Company

For information on the persons who will, immediately following the completion of the **[REDACTED]**, having or be deemed or taken to have beneficial interests or short position in our Shares or underlying Shares which would fall to be disclosed to our Company under the provisions of Divisions of 2 and 3 of Part XV of the SFO, or directly or indirectly be entitled to exercise, or control the exercise of, 10% or more of the voting power at any meeting of our Company, see "Substantial Shareholders."

Save as disclosed in the section headed "Substantial Shareholders" in this Document, as of the Latest Practicable Date, our Directors were not aware of any persons who would, immediately following the completion of the **[REDACTED]**, having or be deemed or taken to the beneficial interests or short position in our Shares or underlying Shares which would fall to be disclosed to our Company under the provisions of Divisions of 2 and 3 of Part XV of the SFO, or directly or indirectly be entitled to exercise, or control the exercise of, 10% or more of the voting power at any general meeting of our Company.

(ii) Interest in the Shares of Our Company's Subsidiaries

So far as the Directors are aware, immediately following completion of the **[REDACTED]**, apart from our Company, the following persons (not being a Director or a chief executive) will, directly or indirectly, be interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any other member of our Group:

Member of our Group	Name of substantial shareholder	Nature of interests	Approximate percentage of interest in the member of our Group
Rong Tai Lanzhou	Gansu Jianyou Pharmaceutical Co., Ltd. (甘肅健友藥業有限公司)	Beneficial interest	49%
	Mr. Han Hekan	Interest in controlled corporation	43.3%
Rong Tai Shenyang	Shenyang Manxin Business Service Partnership (Limited Partnership) (瀋陽滿鑫商務服務合夥企業(有限合夥))	Beneficial interest	49%
	Mr. Yu Shihui	Interest in controlled corporation	27.44%
Rong Tai Chongqing	Chongqing Rongli Enterprise Management Partnership (Limited Partnership) (重慶融粒企業管理合夥企業(有限合夥))	Beneficial interest	10%
Wuhan Yikangsi	Wuhan Yirongkang Enterprise Management Partnership (Limited Partnership) (武漢益融康企業管理合夥企業(有限合夥))	Beneficial interest	20%

So far as set out above, our Directors are not aware of any persons (other than our Directors or chief executive) who will, immediately following the completion of the **[REDACTED]**, directly or indirectly, be interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any other member of our Group.

3. Disclaimers

(i) Save as disclosed in "History, Development and Corporate Structure" and this Appendix, none of our Directors or any of the parties listed in "—C. Other Information—7. Qualifications and Consents of Experts" in this section:

(a) is interested in our promotion, or in any assets which, within the two years immediately preceding the date of this Document, have been acquired or disposed of by or leased to us, or are proposed to be acquired or disposed of by or leased to our Company; or

(b) is materially interested in any contract or arrangement subsisting at the date of this Document that is significant in relation to our business;

(ii) Save as disclosed in this Appendix and in connection with the **[REDACTED]**, none of the parties listed in "—C. Other Information—7. Qualifications and Consents of Experts" in this section:

(a) is interested legally or beneficially in any Shares in any member of our Group; or

(b) has any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for any securities in any member of our Group;

(iii) None of our Directors or their close associates or any Shareholders of our Company who, to the knowledge of our Directors, owns more than 5% of our issued share capital has any interest in our top five customers or suppliers; and

(iv) Save as disclosed in "Substantial Shareholders," none of our Directors is a director or employee of a company that has an interest in the share capital of our Company which, once the H Shares are **[REDACTED]** on the Stock Exchange, would have to be disclosed pursuant to Divisions 2 and 3 of Part XV of the SFO.

C. OTHER INFORMATION

1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to fall on our Company or any of our subsidiaries.

2. Litigation

As of the Latest Practicable Date, we were not engaged in any litigation, arbitration or claim of material importance and no litigation arbitration or claim of material importance and no litigation, arbitration or claim of material importance was known to our Directors to be pending or threatened by or against us, that would have a material adverse effect on our financial condition or results of operations.

3. The Sole Sponsor

The Sole Sponsor has made an application on behalf of our Company to the Listing Committee for the **[REDACTED]** of, and permission to deal in, the H Shares to be converted from Unlisted Shares and the H Shares to be issued pursuant to the **[REDACTED]**. All necessary arrangements have been made to enable our H Shares to be admitted into CCASS.

The Sole Sponsor has confirmed that they satisfy the independence criteria applicable to a sponsor set out in Rule 3A.07 of the Listing Rules.

The total amount of sponsor's fee in connection with the **[REDACTED]** is US$500,000.

4. Compliance Advisor

Our Company has appointed Altus Capital Limited as our Compliance Advisor in compliance with Rule 3A.19 of the Listing Rules.

5. Preliminary Expenses

We have not incurred any material preliminary expenses in relation to the incorporation of our Company.

6. Taxation of Holder of H Shares

The sale, purchase and transfer of H Shares are subject to Hong Kong SAR stamp duty if such sale, purchase and transfer are effected on the H Share register of members of our Company, including in circumstances where such transaction is effected on the Stock Exchange. The current rate of Hong Kong SAR stamp duty for such sale, purchase and transfer is a 0.1% of the consideration or, if higher, the fair value of the H Shares being sold or transferred. For further information in relation to taxation, see "Regulatory Overview—Regulations Relating to Taxation".

7. Qualifications and Consents of Experts

The following are the qualifications of the experts who have given opinion or advice which are contained in this Document:

Name	Qualifications
CITIC Securities (Hong Kong) Limited	A licensed corporation to conduct Type 4 (advising on securities) and Type 6 (advising on corporate finance) regulated activities under the SFO
Global Law Office	PRC Legal Advisor to our Company
Frost & Sullivan	Industry consultant
Ernst & Young	Certified Public Accountants and Registered Public Interest Entity Auditor under the Accounting and Financial Reporting Council Ordinance

Name	Qualifications
	Registered Public Interest Entity Auditor under Accounting and Financial Reporting Council Ordinance (Chapter 588 of the Laws of Hong Kong)

As of the Latest Practicable Date, none of the experts named above had any shareholding interest in our Company or any of our subsidiaries or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group.

8. Promoters

The promoters of our Company are all of the then shareholders of our Company as at July 18, 2022 before our conversion into a joint stock company. Save as disclosed in this Document, within the two years immediately preceding the date of this Document, no cash, securities or benefit has been paid, allotted or given, or is proposed to be paid, allotted or given to the promoters named above in connection with the **[REDACTED]** or the related transactions described in this Document.

9. Bilingual Document

The English language and Chinese language versions of this Document are being published separately in reliance upon the exemption provided by section 4 of the Companies Ordinance (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

10. Binding Effect

This Document shall have the effect, if an application is made in pursuance of this Document, of rendering all persons concerned bound by all of the provisions (other than the penal provisions) of Sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance in so far as applicable.

11. No Material Adverse Change

Our Directors confirm that there has been no material adverse change in our financial, trading position or prospects since December 31, 2025, being the date of our combined financial statements as set out in "Accountants' Report" in Appendix I to this Document up to the date of this Document.

12. Miscellaneous

(i) Save as disclosed in "History, Development and Corporate Structure" and this Appendix and in connection with the **[REDACTED]**, within the three years immediately preceding the date of this Document:

  (a) no share or loan capital of our Company or any of its subsidiaries has been issued nor agreed to be issued fully or partly paid either for cash or for a consideration other than cash;

  (b) no commissions, discounts, brokerage fee or other special terms have been granted in connection with the issue or sale of any Share or loan capital of our Company or any of our subsidiaries;

(c) no Share or loan capital of our Company is under option or is agreed conditionally or unconditionally to be put under option; and

(d) no commission has been paid or is payable for subscribing or agreeing to subscribe, or procuring or agreeing to procure the subscriptions of any share in our Company or any of our subsidiaries;

(ii) We have not issued nor agreed to issue any founder shares, management shares or deferred shares;

(iii) There are no arrangements under which future dividends are waived or agreed to be waived;

(iv) There are no procedures for the exercise of any right of pre-emption or transferability of subscription rights;

(v) There have been no interruptions in our business which may have or have had a significant effect on our financial position in the 12 months preceding the date of this Document;

(vi) There are no restrictions affecting the remittance of profits or repatriation of capital by us into Hong Kong SAR from outside Hong Kong SAR;

(vii) No part of the equity or debt securities of our Company or any member of our Group, if any, is currently **[REDACTED]** on or dealt in on any stock exchange or trading system, and no such **[REDACTED]** or permission to **[REDACTED]** on any stock exchange other than the Stock Exchange is currently being or agreed to be sought; and

(viii) Our Company has no outstanding convertible debt securities or debentures.